Peripheral Inflammatory Biomarkers and Risk of Parkinson's Disease
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Experimental and postmortem evidence indicates a role of neuroinflammation in the pathogenesis of Parkinson's disease. The authors prospectively examined whether plasma concentrations of inflammatory biomarkers assessed before Parkinson's disease diagnosis were predictive of future risk of the disease in a nested case-control study in the United States (1993-2002), including 84 incident cases and 165 matched controls. Blood was collected from patients on average 4.3 years before the diagnosis. After adjustment for potential confounders, higher level of interleukin-6 was associated with a greater risk of Parkinson's disease. Compared with the lowest quintile, the odds ratios were 1.5 for the second, 1.6 for the third, 2.7 for the fourth, and 3.4 for the fifth quintiles (p for trend = 0.03). In contrast, concentrations of other inflammatory biomarkers including C-reactive protein, fibrinogen, and tumor necrosis factor-alpha receptors were not related to the risk. These data suggest that men with high plasma concentrations of interleukin-6 have an increased risk of developing Parkinson's disease. However, this finding should be interpreted with caution because of the small sample size and the lack of associations with other biomarkers of inflammation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Goodwill, M. H., Lawrence, D. A., & Seegal, R. F. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.030 · Cited by 15
RetractedRidker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850 · cited 1×
“High-sensitivity C-reactive protein, an important risk factor for cardiovascular disease (23) and possibly dementia (24), has not been implicated in any Parkinson’s disease research.”
BackgroundMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Plasma Adiponectin Levels and Risk of Myocardial Infarction in Men
Pischon, T. (2004) · JAMA · doi:10.1001/jama.291.14.1730 · Cited by 1,773
Inflammatory Markers and the Risk of Coronary Heart Disease in Men and Women
Pai, J. K., Pischon, T., Ma, J., Manson, J. E., Hankinson, S. E., Joshipura, K., Curhan, G. C., Rifai, N., Cannuscio, C. C., Stampfer, M. J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040967 · Cited by 1,174
Elevations of Inflammatory and Procoagulant Biomarkers in Elderly Persons With Renal Insufficiency
Shlipak, M. G., Fried, L. F., Crump, C., Bleyer, A. J., Manolio, T. A., Tracy, R. P., Furberg, C. D., & Psaty, B. M. (2003) · Circulation · doi:10.1161/01.cir.0000042700.48769.59 · Cited by 810
Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease
Hughes, A. J., Daniel, S. E., & Lees, A. J. (2001) · Neurology · doi:10.1212/wnl.57.8.1497 · Cited by 807
Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging study
Schmidt, R., Schmidt, H., Curb, J. D., Masaki, K., White, L. R., & Launer, L. J. (2002) · Annals of Neurology · doi:10.1002/ana.10265 · Cited by 710
Prospective Study of Caffeine Consumption and Risk of Parkinson’s Disease in Men and Women
Ascherio, A., Zhang, S. M., Hernán, M. A., Kawachi, I., Colditz, G. A., Speizer, F. E., & Willett, W. C. (2001) · Annals of Neurology · doi:10.1002/ana.1052 · Cited by 677 · cited 1×
“After blood collection, 84 incident Parkinson’s disease cases were identified according to a standardized procedure (7).”
MethodSelf-citationNonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 634
Self-citationInflammation and neurodegeneration in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.01.005 · Cited by 625
Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M., & Nagatsu, T. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12706-3 · Cited by 545
Interleukin-6 (IL-6)—A molecule with both beneficial and destructive potentials
Gadient, R. A., & Otten, U. H. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00021-x · Cited by 481
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
Chen, H., Jacobs, E., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · Annals of Neurology · doi:10.1002/ana.20682 · Cited by 472
Self-citationInflammatory Process in Parkinsons Disease: Role for Cytokines
Nagatsu, T., & Sawada, M. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612053381620 · Cited by 412
McGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400 · cited 1×
“Further support for this hypothesis includes marked and ongoing gliosis around dopaminergic neurons in monkey (28) and human parkinsonian sufferers (29) years after exposures to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, suggesting a chronic and self-perpetuated neuroinflammation process in parkinsonism.”
BackgroundPlasma Urate and Risk of Parkinson's Disease
Weisskopf, M., O'Reilly, E., Chen, H., Schwarzschild, M., & Ascherio, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm127 · Cited by 390
Self-citationPhysical activity and the risk of Parkinson disease
Chen, H., Zhang, S. M., Schwarzschild, M. A., Hernán, M. A., & Ascherio, A. (2005) · Neurology · doi:10.1212/01.wnl.0000151960.28687.93 · Cited by 371
Self-citationAssociation of circulating TNF-α and IL-6 with ageing and parkinsonism
Dobbs, R. J., Charlett, A., Purkiss, A. G., Dobbs, S. M., Weller, C., & Peterson, D. W. (1999) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1999.tb00721.x · Cited by 324
Serum uric acid levels and the risk of Parkinson disease
de Lau, L. M. L., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20663 · Cited by 301
Weight loss in Parkinson's disease
Chen, H., Zhang, S. M., Hernán, M. A., Willett, W. C., & Ascherio, A. (2003) · Annals of Neurology · doi:10.1002/ana.10577 · Cited by 297
Self-citationObservations on Serum Uric Acid Levels and the Risk of Idiopathic Parkinson's Disease
Davis, J. W., Grandinetti, A., Waslien, C. J., Ross, G. W., White, L. R., & Morens, D. M. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008954 · Cited by 216
C-Reactive Protein and Incident Cardiovascular Events Among Men With Diabetes
Schulze, M. B., Rimm, E. B., Li, T., Rifai, N., Stampfer, M. J., & Hu, F. B. (2004) · Diabetes Care · doi:10.2337/diacare.27.4.889 · Cited by 180
Stypuła, G., Radek, M., Stepien, H., Żylińska, K., & Pawlikowski, M. (1996) · NeuroImmunoModulation · doi:10.1159/000097237 · Cited by 134
Inflammatory markers and the risk of coronary heart disease in men and women
Pai, J. K., Pischon, T., & Ma, J. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.02.067 · Cited by 120
Increased vulnerability of dopaminergic neurons in MPTP‐lesioned interleukin‐6 deficient mice
Bolin, L. M., Strycharska-Orczyk, I., Murray, R., Langston, J. W., & Monte, D. A. D. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01131.x · Cited by 97
Role of TNF-α Receptors in Mice Intoxicated with the Parkinsonian Toxin MPTP
Rousselet, E., Callebert, J., Parain, K., Joubert, C., Hunot, S., Hartmann, A., Jacque, C., Pérez-Díaz, F., Cohen‐Salmon, C., Launay, J., et al. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7960 · Cited by 94
Role of the Brain in Interleukin-6 Modulation
Terreni, L., & Simoni, M. G. D. (1998) · NeuroImmunoModulation · doi:10.1159/000026339 · Cited by 36
Inflammatory Proteins in Plasma and the Risk of Dementia: The Rotterdam Study
Engelhart, M. J., Geerlings, M. I., Meijer, J., Kiliaan, A., Ruitenberg, A., van Swieten, J. C., Stijnen, T., Hofman, A., Witteman, J. C. M., & Breteler, M. M. B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.668 · Cited by 10 · cited 1×
“In addition, the peripheral C-reactive protein concentration is much higher than that in the central nervous system (25); therefore, even a marked C-reactive protein elevation in the central nervous system may not be adequate to increase its circulation level.”
BackgroundLangston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Cited by
The JAK/STAT signaling pathway: from bench to clinic
Hu, X., li, J., Fu, M., Zhao, X., & Wang, W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00791-1 · Cited by 2,633
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Epidemiology and etiology of Parkinson's disease: a review of the evidence
Wirdefeldt, K., Adami, H.-O., Cole, P., Trichopoulos, D., & Mandel, J. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9581-6 · Cited by 1,199
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 778
Metadata
- Authors
- Chen, H., O'Reilly, E. J., Schwarzschild, M. A., & Ascherio, A.
- Venue
- American Journal of Epidemiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-11-15
- Volume
- 167
- Issue
- 1
- Pages
- 90-95
- ISSN
- 0002-9262 (ISSN-L)
- 1476-6256
- OpenAlex
- W2166688610
- Cited by
- 317
- References
- 30
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.